Chief Medical Officer, Wave Neuroscience
Appears in 1 story
Presented the trial figures in the October 2026 announcement
The Food and Drug Administration cleared a personalized magnetic brain therapy for PTSD in June 2026. The maker's trial reports a 68% remission rate, more than four times the maximum seen in a 2020 review of standard PTSD medications.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
